Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer


 

Interview with Kathleen Moore, MD

Track 1: Genetic testing algorithms for patients with newly diagnosed ovarian cancer
Track 2: Challenges associated with somatic and germline testing in ovarian cancer
Track 3: Importance of genomic profiling for all patients with newly diagnosed ovarian cancer
Track 4: Genetic counseling for patients with ovarian cancer
Track 5: SOLO-1 trial: Improvement in progression-free survival with olaparib as maintenance therapy for patients with advanced ovarian cancer and a BRCA mutation after a response to first-line platinum-based chemotherapy
Track 6: Risk of recurrence with olaparib versus placebo as maintenance therapy in the SOLO-1 trial
Track 7: Integration of bevacizumab into the treatment algorithm for patients with advanced ovarian cancer and a germline BRCA mutation
Track 8: PAOLA-1: An ongoing Phase III trial evaluating bevacizumab with or without olaparib as maintenance therapy for patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy and bevacizumab
Track 9: Perspective on the timing of initiation of a PARP inhibitor as maintenance therapy for patients with ovarian cancer
Track 10: Side effects associated with olaparib and rate of discontinuation on the SOLO-1
Track 11: Counseling patients with advanced ovarian cancer and a germline BRCA mutation about the risk of developing breast cancer
Track 12: Role of PARP inhibitors for patients with ovarian cancer and a germline PALB2 mutation
Track 13: Therapeutic approach for patients with advanced ovarian cancer and a BRCA1 Q780E mutation of unknown significance
Track 14: Selection of therapy for patients with recurrent, platinum-sensitive ovarian cancer and a BRCA mutation
Track 15: Efficacy of bevacizumab for patients with platinum-sensitive relapsed ovarian cancer
Track 16: SOLO-3: An ongoing Phase III trial evaluating olaparib versus chemotherapy for patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation who have received 2 or more lines of prior chemotherapy
Track 17: Choice of therapy for patients with BRCA wild-type platinum-sensitive ovarian cancer
Track 18: Results from the ongoing Phase II QUADRA trial of niraparib monotherapy for patients with relapsed ovarian cancer who have received 3 or more lines of chemotherapy
Track 19: Niraparib dose modification to mitigate thrombocytopenia
Track 20: Management of elevated serum creatinine levels associated with olaparib and rucaparib
Track 21: Ongoing studies investigating the clinical benefit of PARP inhibitor therapy for patients with ovarian cancer and prior exposure to a PARP inhibitor
 
FACULTY
 
Kathleen Moore, MD
Jim and Christy Everest Endowed Chair in Cancer Research
Associate Director, Clinical Research
Director
Oklahoma TSET Phase I Program
Stephenson Cancer Center 
Associate Professor
Section of Gynecologic Oncology
Director
Gynecologic Oncology Fellowship
Department of Obstetrics
and Gynecology
University of Oklahoma
Health Sciences Center
Oklahoma City, Oklahoma
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida